ABSTRACT
Objective In sub-Saharan Africa, hepatitis B is the principal cause of liver disease. Non-invasive biomarkers of liver fibrosis are needed to identify patients requiring antiviral treatment. We assessed aspartate aminotransferase-to-platelet ratio index (APRI), gamma-glutamyl transferase-to-platelet ratio (GPR) and FIB-4 to diagnose significant fibrosis and cirrhosis in an individual patient data (IPD) meta-analysis.
Design In total, 3,549 patients from 12 cohorts of HBsAg positive individuals in 8 sub-Saharan African countries were included. Transient elastography was used as a reference test for cirrhosis (>12.2 kPa), excluding patients who were pregnant, had hepatitis C, D, or HIV co-infection, were on hepatitis B therapy, or had acute hepatitis. A bivariate Bayesian IPD model was fitted with patient-level covariates and study-level random effects.
Results APRI and GPR had the best discriminant performance (area under receiver operating curve 0.81 and 0.82) relative to FIB-4 (0.77) for cirrhosis. The World Health Organization (WHO) recommended APRI threshold of ≥2.0 was associated with a sensitivity and specificity (95% credible interval) of 16.5% (12.5-20.5) and 99.5% (99.2-99.7) for cirrhosis. For APRI, we identified an optimised rule-in threshold for cirrhosis (cut-off 0.65) with a sensitivity and specificity of 56.2% (50.5-62.2) and 90.0% (89.0-91.0), and an optimised rule-out threshold (cut-off 0.36) with a sensitivity and specificity of 80.6% (76.1-85.1) and 64.3% (62.8-65.8).
Conclusions The WHO recommended APRI threshold of 2.0 is too high to diagnose cirrhosis in sub-Saharan Africa. We identified new and optimised rule-in and rule-out thresholds for cirrhosis, with direct consequences for treatment guidelines in this setting.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
National ethics committees / IRBs in all 8 countries gave ethical approval for this work: Ethiopia National Research Ethics Review Committee, Ethiopia (Ref.: 3.10/829/07). Regional Committee for Medical and Health Research Ethics, Norway (Ref.: 2014/1146). Malawi National Health Sciences Research Committee of Malawi (Ref.: 16/11/1698 and 15/5/1599). University of Liverpool, UK (Ref.: 1954). Zambia University of Zambia Biomedical Research Ethics Committee (Ref.: 013-09-15). South Africa University of Cape Town Human Research Ethics Committee, South Africa (Ref.: 667/2020). Stellenbosch University Human Research Ethics Committee, South Africa (Ref.: N17/01/013 and S13/04/072). University of Oxford Tropical Research Ethics Committee, UK (Ref.: OXTREC 01-18). Nigeria Jos University Research Ethics Committee, Nigeria (Ref.: JUTH/DCS/ADM/127/XIX/5962). The Gambia The Government of The Gambia and Medical Research Council (MRC) Gambia Joint Ethics Committee (Ref.: SCC1266). Senegal Senegalese National Health Research Ethics Committee (Ref.: SEN11/34 and SEN19/11). Burkina Faso Yalgado Ouedraogo University Hospital Center Institutional Review Board, Burkina Faso (Ref.: 0782).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
